Optoacoustic properties of Doxorubicin - A pilot study

Melanie A. Kimm; Claudia Gross; Xose Luis Déan-Ben; Avihai Ron; Ernst J. Rummeny; Hsiao Chun Amy Lin; Carsten Höltke; Daniel Razansky; Moritz Wildgruber

doi:10.1371/journal.pone.0217576

Optoacoustic properties of Doxorubicin - A pilot study

Melanie A. Kimm
, Claudia Gross
, Xose Luis Déan-Ben
, Avihai Ron
, Ernst J. Rummeny
, Hsiao Chun Amy Lin
, Carsten Höltke
, Daniel Razansky
, Moritz Wildgruber

Former organisations of Medicine and Health

Technical University of Munich
University of Zurich
ETH Zürich
Helmholtz Zentrum München German Research Center for Environmental Health
Universitätsklinikum Münster

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Doxorubicin (DOX) is a widely used chemotherapeutic anticancer drug. Its intrinsic fluorescence properties enable investigation of tumor response, drug distribution and metabolism. First phantom studies in vitro showed optoacoustic property of DOX. We therefore aimed to further investigate the optoacoustic properties of DOX in biological tissue in order to explore its potential as theranostic agent. We analysed doxorubicin hydrochloride (Dox.HCl) and liposomal encapsulated doxorubicin hydrochloride (Dox.Lipo), two common drugs for anticancer treatment in clinical medicine. Optoacoustic measurements revealed a strong signal of both doxorubicin substrates at 488 nm excitation wavelength. Post mortem analysis of intra-tumoral injections of DOX revealed a detectable optoacoustic signal even at three days after the injection. We thereby demonstrate the general feasibility of doxorubicin detection in biological tissue by means of optoacoustic tomography, which could be applied for high resolution imaging at mesoscopic depths dictated by effective penetration of visible light into the biological tissues.

Original language	English
Article number	e0217576
Journal	PLoS ONE
Volume	14
Issue number	5
DOIs	https://doi.org/10.1371/journal.pone.0217576
State	Published - May 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1371/journal.pone.0217576

Cite this

@article{673ea941c0734553ac2eb4ef9c84839b,

title = "Optoacoustic properties of Doxorubicin - A pilot study",

abstract = "Doxorubicin (DOX) is a widely used chemotherapeutic anticancer drug. Its intrinsic fluorescence properties enable investigation of tumor response, drug distribution and metabolism. First phantom studies in vitro showed optoacoustic property of DOX. We therefore aimed to further investigate the optoacoustic properties of DOX in biological tissue in order to explore its potential as theranostic agent. We analysed doxorubicin hydrochloride (Dox.HCl) and liposomal encapsulated doxorubicin hydrochloride (Dox.Lipo), two common drugs for anticancer treatment in clinical medicine. Optoacoustic measurements revealed a strong signal of both doxorubicin substrates at 488 nm excitation wavelength. Post mortem analysis of intra-tumoral injections of DOX revealed a detectable optoacoustic signal even at three days after the injection. We thereby demonstrate the general feasibility of doxorubicin detection in biological tissue by means of optoacoustic tomography, which could be applied for high resolution imaging at mesoscopic depths dictated by effective penetration of visible light into the biological tissues.",

author = "Kimm, \{Melanie A.\} and Claudia Gross and D{\'e}an-Ben, \{Xose Luis\} and Avihai Ron and Rummeny, \{Ernst J.\} and Lin, \{Hsiao Chun Amy\} and Carsten H{\"o}ltke and Daniel Razansky and Moritz Wildgruber",

note = "Publisher Copyright: {\textcopyright} 2019 Kimm et al.",

year = "2019",

month = may,

doi = "10.1371/journal.pone.0217576",

language = "English",

volume = "14",

journal = "PLoS ONE",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "5",

}

TY - JOUR

T1 - Optoacoustic properties of Doxorubicin - A pilot study

AU - Kimm, Melanie A.

AU - Gross, Claudia

AU - Déan-Ben, Xose Luis

AU - Ron, Avihai

AU - Rummeny, Ernst J.

AU - Lin, Hsiao Chun Amy

AU - Höltke, Carsten

AU - Razansky, Daniel

AU - Wildgruber, Moritz

PY - 2019/5

Y1 - 2019/5

N2 - Doxorubicin (DOX) is a widely used chemotherapeutic anticancer drug. Its intrinsic fluorescence properties enable investigation of tumor response, drug distribution and metabolism. First phantom studies in vitro showed optoacoustic property of DOX. We therefore aimed to further investigate the optoacoustic properties of DOX in biological tissue in order to explore its potential as theranostic agent. We analysed doxorubicin hydrochloride (Dox.HCl) and liposomal encapsulated doxorubicin hydrochloride (Dox.Lipo), two common drugs for anticancer treatment in clinical medicine. Optoacoustic measurements revealed a strong signal of both doxorubicin substrates at 488 nm excitation wavelength. Post mortem analysis of intra-tumoral injections of DOX revealed a detectable optoacoustic signal even at three days after the injection. We thereby demonstrate the general feasibility of doxorubicin detection in biological tissue by means of optoacoustic tomography, which could be applied for high resolution imaging at mesoscopic depths dictated by effective penetration of visible light into the biological tissues.

AB - Doxorubicin (DOX) is a widely used chemotherapeutic anticancer drug. Its intrinsic fluorescence properties enable investigation of tumor response, drug distribution and metabolism. First phantom studies in vitro showed optoacoustic property of DOX. We therefore aimed to further investigate the optoacoustic properties of DOX in biological tissue in order to explore its potential as theranostic agent. We analysed doxorubicin hydrochloride (Dox.HCl) and liposomal encapsulated doxorubicin hydrochloride (Dox.Lipo), two common drugs for anticancer treatment in clinical medicine. Optoacoustic measurements revealed a strong signal of both doxorubicin substrates at 488 nm excitation wavelength. Post mortem analysis of intra-tumoral injections of DOX revealed a detectable optoacoustic signal even at three days after the injection. We thereby demonstrate the general feasibility of doxorubicin detection in biological tissue by means of optoacoustic tomography, which could be applied for high resolution imaging at mesoscopic depths dictated by effective penetration of visible light into the biological tissues.

UR - https://www.scopus.com/pages/publications/85066505089

U2 - 10.1371/journal.pone.0217576

DO - 10.1371/journal.pone.0217576

M3 - Article

C2 - 31150471

AN - SCOPUS:85066505089

SN - 1932-6203

VL - 14

JO - PLoS ONE

JF - PLoS ONE

IS - 5

M1 - e0217576

ER -

Optoacoustic properties of Doxorubicin - A pilot study

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this